Abstracts tagged "T Cell"

Abstract Number: 0987 • ACR Convergence 2025
S-4321, a novel dual-cell bifunctional PD-1:FcγRIIb selective agonist antibody for autoimmune disease, maintains expression of PD-1 on target cells and enhances inhibitory receptor expression on T cells in vivo
Julia Manasson¹, Michael Cianci², Minasri Borah², Stephanie Grebinoski², Joshua Vitlip², Stephen Lutz², Ishan Sharma², Elliott Wittenberg², Allison Colthart², Samuel Perry², Maria Cecilia Ramello², Chelsea R. Parker Harp², Jyothsna Visweswaraiah², Ryan Peckner², Alex Pellerin², Heather Vital³, John Sundy⁴, Nathan Higginson-Scott², Kevin L. Otipoby² and Daniela Cipolletta², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Durham, NC
Background/Purpose: S-4321 is a novel antibody that agonizes the inhibitory PD-1 checkpoint receptor on T cells without competing for binding with its natural ligand, PD-L1,…
Abstract Number: 0869 • ACR Convergence 2025
PD-1 inhibitor unleashes pathogenic CD8+ T cells and induce arthritis in collagen-primed mice
Clement Adedeji¹, Muhammad Hamdan¹, Hong-Jai Park², Kelsey Wang¹ and Sang Kim³, ¹Yale University, New Haven, ²Yale University, New Haven, CT, ³Yale University, Branford, CT
Background/Purpose: Background/Purpose: Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events, including inflammatory arthritis (ICI-arthritis). The pathophysiology of ICI-arthritis, particularly the role of T…
Abstract Number: 0586 • ACR Convergence 2025
Immune Checkpoint agonists: A New horizon for treatment of psoriatic arthritis
Siba Raychaudhuri¹, Christine Abria² and Smriti K Raychaudhuri³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²Sacramento VA Medical Center, Mather, CA, ³Sacramento VA Medical Center, Davis, CA
Background/Purpose: Check point inhibitor PD-1 (programmed death protein 1) is upregulated during T lymphocyte activation and is important for limiting the duration of activation. Thus,…
Abstract Number: 1529 • ACR Convergence 2025
Updated Phase 1 Trial Data Assessing the Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor T Cell Therapy Using a Next-Generation Process for Severe, Refractory SLE
Georg Schett¹, David Simon², Margrit Wiesendanger³, Anca Askanase⁴, Vikas Majithia⁵, Neil Kramer⁶, Jacques Morel⁷, Philip J. Mease⁸, Ellen De Langhe⁹, Amit Saxena¹⁰, dominique Farge¹¹, Alain Lescoat¹², Alisha Desai¹³, Griff McTume¹⁴, Whitney Handy¹⁴, Sharmila Das¹³, Jerill Thorpe¹⁴, Alexis Melton¹⁴, Ashley Koegel¹⁴ and Emily Littlejohn¹⁵, ¹Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ²Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Columbia University Medical Center, New York, NY, ⁵Mayo Clinic Hospital, Jacksonville, FL, ⁶Overlook Medical Center; Atlantic Medical Group, Atlantic Health System, Summit, NJ, ⁷CHU and University of Montpellier, Montpellier, France, ⁸Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁹University Hospitals Leuven, Leuven, Belgium, ¹⁰Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ¹¹Hôpital Saint-Louis, Paris, France, ¹²CHU Rennes University Hospital, Rennes, France, ¹³Bristol Myers Squibb, Princeton, NJ, ¹⁴Bristol Myers Squibb, Princeton, ¹⁵Cleveland Clinic, Cleveland, OH
Background/Purpose: BMS-986353 (CC-97540; CD19 NEX-T) is a CD19-directed chimeric antigen receptor (CAR) T cell therapy that expresses the same CAR as lisocabtagene maraleucel (liso-cel); it…
Abstract Number: 0986 • ACR Convergence 2025
LBL-053, A Novel Anti-TL1A/p40 Bispecific Antibody for the Treatment of Autoimmune Disorders.
Shuijun Hu¹, Fengxia Li¹, Aixia Liu¹, Hailin Wang¹, Xiaoxiao Liu¹, Jianming Sun¹, Yurong Qin¹, Guojin Wu¹, Jing Guan¹, Hui Yuwen¹, Jordan Zhu², Xiaoqiang Kang¹, Xiao Huang¹ and Hong Ling¹, ¹Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), ²Nanjing Leads Biolabs Co., Ltd., Nan Jing
Background/Purpose: Inflammatory bowel disease (IBD) is a chronic, immune-mediated, inflammatory disease of the digestive tract. Several biological agents have greatly improved clinical course, remission, and…
Abstract Number: 0850 • ACR Convergence 2025
Single-cell RNA-seq analysis of synovial CD4+ T cells identifies a novel biomarker and therapeutic target in human rheumatoid arthritis
Akinori Murakami¹, Rinko Akamine¹, Koichi Murata¹, Kohei Nishitani¹, Hiromu Ito², Ryu Watanabe³, Takayuki Fujii¹, Takeshi Iwasaki¹, Yuki Masuo⁴, Osamu Iri¹, Shinichiro Nakamura¹, Shinichi Kuriyama¹, Yugo Morita¹, Yasuhiro Murakawa⁵, Chikashi Terao⁶, Yukinori Okada⁷, Motomu Hashimoto³, Shuichi Matsuda¹, Hideki Ueno¹ and Hiroyuki Yoshitomi¹, ¹Kyoto University, Kyoto, Japan, ²Kyoto University / Kurashiki Central Hospital, Kyoto, Japan, ³Osaka Metropolitan University, Osaka, Japan, ⁴Graduate school of medicine, Kyoto University, Kyoto, Japan, ⁵Kyoto University / RIKEN, Kyoto, Japan, ⁶RIKEN, Tokyo, Japan, ⁷The University of Tokyo / Osaka University / RIKEN, Tokyo, Japan
Background/Purpose: CD4+ T cells play a central role in the pathogenesis of human rheumatoid arthritis (RA). However, therapies targeting CD4+ T cell-derived humoral factors, including…
Abstract Number: 1508 • ACR Convergence 2025
Dissecting the Role of T Cell Subsets and Complements in Lupus Pathogenesis in Systemic Lupus Erythematosus Patients with Obesity
Sheila Serin¹, Megan Schluentz¹, Chandana Keshavamurthy¹, Alexandra Reese¹, Sneha Centala¹, Bettina Boone¹, Samantha Ahrens², William Davis³, Robert Quinet¹, Jerald Zakem⁴, Samina Hayat⁵, Sarwat Umer⁶, Teresa leeth⁷, Daniyal Nadeem⁷ and Xin Zhang⁸, ¹Department of Rheumatology, Ochsner Health, New Orleans, LA, ²Multi-specialty Clinical Research, Ochsner Health, New Orleans, LA, ³Ochsner Health System, New Orleans, LA, ⁴Ochsner Health Systems, Metairie, LA, ⁵Louisiana state university Shreveport, Shreveport, LA, ⁶LSUHSC Shreveport, Shreveport, LA, ⁷Louisiana State University Health Science, Shreveport, LA, ⁸Ochsner Medical Center, New Orleans, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by systemic inflammation, autoantibody production, and multiorgan involvement. Although genetic, hormonal, and environmental factors…
Abstract Number: L03 • ACR Convergence 2024
CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus
Kyleigh Brimmer¹, Olivia Antao¹, Daniel Mayer¹, Gina Sanchez¹, Rebecca Francis¹, Htay Htay Kyi², Mary Salim², Boyan Xia², Eugenio Capitle² and Jason Weinstein¹, ¹Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ, ²Division of Allergy, Immunology and Rheumatology, University Hospital, Newark, NJ
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…
Abstract Number: L16 • ACR Convergence 2024
Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial
Megan Clowse¹, David Isenberg², Joan Merrill³, Thomas Dörner⁴, Michelle Petri⁵, Edward Vital⁶, Eric Morand⁷, Teri Jimenez⁸, Stephen Brookes⁹, Janine Gaiha-Rohrbach¹⁰, Christophe Martin¹¹, Annette Nelde¹² and Christian Stach¹³, ¹Division of Rheumatology and Immunology, Duke University, Durham, NC, ²Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁸UCB, Raleigh, NC, ⁹Biogen, Maidenhead, United Kingdom, ¹⁰Biogen, Cambridge, MA, ¹¹UCB, Slough, United Kingdom, ¹²Biogen, Baar, Switzerland, ¹³UCB, Monheim am Rhein, Germany
Background/Purpose: Dapirolizumab pegol (DZP) is a novel, polyethylene glycol (PEG)-conjugated antigen-binding (Fab') fragment, lacking an Fc domain, that inhibits CD40L signaling. By binding to CD40L,…
Abstract Number: 0003 • ACR Convergence 2024
CLN-978, a CD19-directed T Cell Engager (TCE), Leads to Rapid and Deep B Cell Depletion and Has Broad Potential for Development in Autoimmune Diseases
Máire F. Quigley¹, Jennifer S. Michaelson¹, Jeffrey Jones¹, Farrukh T. Awan², Geoffrey P. Shouse³, Yue Zhang¹, Todd Shearer¹, Judy Inumerable¹, Irina M. Shapiro¹, Patrick A. Baeuerle¹ and Stephen Wax¹, ¹Cullinan Therapeutics, Inc., Cambridge, ²UT Southwestern Medical Center, Dallas, ³City of Hope Comprehensive Cancer Center, Duarte
Background/Purpose: CD19-directed CAR T cell therapy has been reported to induce profound B cell depletion and deep clinical responses, including drug-free remission, in patients with…
Abstract Number: 0499 • ACR Convergence 2024
PD-1hiCXCR5-CD4+T Peripheral Helper Cells Enrich in Rheumatoid Arthritis and Predict Clinical Response to Anti-TNF Treatment
Wanki Ho¹, Huaqun Zhu¹, Hua Ye¹, Dongdong Fu² and Xi Xu¹, ¹Peking University People's Hospital, Beijing, China, ²Xinxiang Central Hospital, Xinxiang, Henan, China (People's Republic)
Background/Purpose: PD-1hiCXCR5-CD4+T peripheral helper cells (Tph) are newly identified pathogenic CD4+T helper cells and participate in rheumatoid arthritis (RA) pathogenesis. However, the clinical significance of…
Abstract Number: 1134 • ACR Convergence 2024
First-in-Human Evaluation of the Safety, Tolerability and Pharmacokinetics of the T Cell Receptor Signal Modulator AX-158
Christopher VanDeusen¹, Andres Gagete¹, Annelize Koch² and D Scott Batty Jr¹, ¹Artax Biopharma, Inc, Cambridge, MA, ²Simbec-Orion, Merthyr Tydfil, Wales, United Kingdom
Background/Purpose: Nck is a cytosolic protein that binds a domain of the T cell receptor (TCR) following TCR interaction to amplify responses from low affinity…
Abstract Number: 1785 • ACR Convergence 2024
Comparative Immuno-Metabolomics Shows Singular Changes in Systemic Lupus Erythematosus Metabolic Phenotype Induced by T-Cell Activation
Martin Stradner¹, Fernanda Monedeiro², Elmar Zuegner², Barbara Prietl³, Monika Oberhuber⁴, Michael Khalil⁵, Christoph Magnes², Hans-Peter Brezinsek¹, Angela Libiseller³ and Thomas Pieber³, ¹Div. of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ²Joanneum Research, Graz, Austria, ³Div. of Endocrinology, Medical University of Graz, Graz, Austria, ⁴CBmed, Graz, Austria, ⁵Dept. of Neurology, Medical University of Graz, Graz, Austria
Background/Purpose: Metabolic processes have a critical role in regulating immune cell function, therefore being relevant to understanding the pathogenesis and progression of autoimmune diseases. Here…
Abstract Number: 1850 • ACR Convergence 2024
Exhausted T-cells Are Increased in Autoimmune Diseases and Predict Response to Anti-TNF in RA and SPA Patients
Samuel Bitoun¹, Marie Naigeon², Matthieu Roulleaux- Dugage², Caroline De Oliveira², Caroline Berthot², Xavier Mariette³, Gaetane Nocturne³ and Nathalie Chaput-Gras², ¹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, ²Laboratoire d'immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy,, Villejuif, France, ³Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France
Background/Purpose: Exhaustion can occur after prolonged activation of T cells limiting their immunosurveillance function leading to cancer emergence. Among the exhaustion markers expressed on T…
Abstract Number: 1988 • ACR Convergence 2024
A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
Marta Cossu¹, Carolina Bobadilla Mendez², Amanda Jackson³, Eugene Myshkin⁴, Grace Liu⁵, Edwin Lam⁶, Ulf H. Beier², Kathleen Weisel², Brittney Scott², Jocelyn H. Leu⁶, Sheng Gao² and Dessislava Dimitrova², ¹Janssen Pharmaceutical Research and Development, a Johnson & Johnson company, Leiden, Netherlands, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, ³Janssen Research & Development, LLC, La Jolla, CA, ⁴Janssen Research & Development, LLC, a Johnson & Johnson company, Cambridge, MA, ⁵Janssen Research & Development, LLC, a Johnson & Johnson company, Raritan, NJ, ⁶Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA
Background/Purpose: Nipocalimab is a human IgG1 monoclonal antibody targeting the neonatal Fc receptor (FcRn) that selectively reduces IgG levels without impacting antigen presentation, T- and…

« Previous Page
1
…
3
4
5
6
7
…
26
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].